The prognostic value of c-myc oncoprotein levels in malignant melanoma

Journal of Plastic, Reconstructive and Aesthetic Surgery

Volumn 61, Issue 4, 2008, Pages 464-

  Ekwobi, C C ^a  

^a ROYAL PRESTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN;

CANCER SURVIVAL; DISEASE CLASSIFICATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; LETTER; MELANOMA; MITOSIS; PRIORITY JOURNAL; PROGNOSIS;

HUMANS; MELANOMA; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 40749098086     PISSN: 17486815     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bjps.2007.12.008     Document Type: Letter

References (4)

1. Ramsden A.J., Grover R., Chana J., et al. A prospective analysis of c-myc oncoprotein levels as a prognostic marker in malignant melanoma. J Plast Reconstr Aesthet Surg 60 (2007) 626-630
2. Lazaris A.C., Theodoropoulos G.E., Aroni K., et al. Immunohistochemical expression of C-myc oncogene, heat shock protein 70 and HLA-DR molecules in malignant cutaneous melanoma. Virchows Archiv 426 (1995) 461-467
3. Kraehn G.M., Utikal J., Udart M., et al. Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. British Journal of Cancer 84 (2001) 72-79
4. Ricaniadis N., Kataki A., Agnantis N., et al. Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma. Eur J Surg Oncol 27 (2001) 88-93